Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

Iberia Pharmaceuticals to open Rs. 70 crore manufacturing unit in India

The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements

USPTO issues final rejection of Rampart IC's radiation shield patent claims

The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent

Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr

Our specialty chemical businesses have continued to perform strongly, growing double digit YoY

iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025

A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide